Scarica l'app Stockscreener
1.99
4.33%
-0.09
Dopo l'orario di chiusura:
2.00
0.01
+0.50%
Precedente Chiudi:
$2.08
Aprire:
$2.08
Volume 24 ore:
17,032
Relative Volume:
0.17
Capitalizzazione di mercato:
$99.19M
Reddito:
-
Utile/perdita netta:
$-6.48M
Rapporto P/E:
-14.53
EPS:
-0.137
Flusso di cassa netto:
$-5.30M
1 W Prestazione:
+0.00%
1M Prestazione:
-6.13%
6M Prestazione:
-66.67%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.99
$2.08
Intervallo di 1 settimana:
$1.90
$2.12
Portata 52W:
$1.85
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Nome
Polaryx Therapeutics Inc
Settore
Industria
Telefono
201-940-7236
Indirizzo
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
1.99 | 103.68M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Iniziato | Maxim Group | Buy |
Polaryx Therapeutics Inc Borsa (PLYX) Ultime notizie
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Polaryx Therapeutics (PLYX) Slips 0.49% to $2.03, Support Holds at $1.93Ease of Movement - vinanet.vn
Polaryx Therapeutics Appoints Will Charlton as Chief Medical Officer Starting September 1, 2026 - Kalkine Media
Polaryx Therapeutics Appoints New Chief Medical Officer - TipRanks
Polaryx Therapeutics Names Will Charlton CMO Ahead of Phase 2 SOTERIA Trial - citybiz
Polaryx appoints Will Charlton as chief medical officer - Investing.com
Polaryx raises $10M for phase II rare disease basket trial - BioWorld News
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer - The Manila Times
A pediatric doctor with over 15 years’ experience joins Polaryx - Stock Titan
Polaryx appoints Will Charlton as chief medical officer By Investing.com - Investing.com South Africa
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx advances preparations for Phase 2 trial launch in Q4 By Investing.com - Investing.com Nigeria
Polaryx advances preparations for Phase 2 trial launch in Q4 - Investing.com India
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx plans to test one oral drug across four childhood diseases - Stock Titan
Polaryx (PLYX) Market: Moves 9.66% Lower to $1.87 in the Current Update; the Supplied Trading Band Runs From $1.78 to $1.96 in Latest TradingShort Term Trading Ideas - siam.in
We Think Polaryx Therapeutics (NASDAQ:PLYX) Can Afford To Drive Business Growth - Sahm
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Polaryx Therapeutics, Inc. (PLYX) - The Globe and Mail
Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M - Stock Titan
Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Raymond James Initiates Polaryx Therapeutics(PLYX.US) With Buy Rating, Announces Target Price $6 - Moomoo
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial - MarketBeat
PLYX Initiated Coverage by Raymond James -- Strong Buy Rating An - GuruFocus
Raymond James Initiates Polaryx Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Polaryx Therapeutics stock with strong buy - Investing.com India
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - 富途牛牛
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis - Kalkine
Polaryx Therapeutics, Inc. SEC Filing (Jul 28, 2026) - Stock Titan
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Se - GuruFocus
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy - GuruFocus
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com Canada
PLYX|Polaryx Therapeutics Ord Shs|Price:2.096|Chg%:-0.024 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – NASDAQ:PLYX - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLYX|Polaryx Therapeutics Ord Shs|Price:2.090|Chg%:-0.010 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX - TradingView
Polaryx Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
Polaryx Therapeutics (PLYX) Slips 3.45%: Support Level Tested at $2.13Iron Condor Alert - vinanet.vn
Polaryx Therapeutics, Inc. Files Form 8-K as Emerging Growth Company on NASDAQ (PLYX) – July 2026 - Minichart
Polaryx Therapeutics' Lisa Bollinger resigns as Chief Medical Officer - TradingView
Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026 - marketscreener.com
Polaryx Sets 2026 Virtual Annual Shareholder Meeting - TipRanks
Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline - Stock Titan
Polaryx Therapeutics (PLYX) Edges Higher Amidst Narrow Trading RangeDouble Top - vinanet.vn
What is HC Wainwright's Forecast for PLYX Q2 Earnings? - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Polaryx Therapeutics Inc Azioni (PLYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):